155 related articles for article (PubMed ID: 36881059)
1. Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.
Kawahara Y; Murata S; Shimizu T; Uesawa Y; Uchida M
In Vivo; 2023; 37(2):955-961. PubMed ID: 36881059
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Omoto T; Asaka J; Sakai T; Sato F; Goto N; Kudo K
Biol Pharm Bull; 2021; 44(5):627-634. PubMed ID: 33952819
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database.
Sato J; Eren T; Murata S; Shimizu T; Uchida M
Anticancer Res; 2022 Dec; 42(12):5917-5925. PubMed ID: 36456140
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2022; 100(7):413-418. PubMed ID: 35504255
[TBL] [Abstract][Full Text] [Related]
8. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
9. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
11. Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Kanbayashi Y; Kobayashi M; Anzai M; Shimizu T; Uchida M
Oncology; 2023; 101(12):817-821. PubMed ID: 37591211
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Sci Rep; 2022 Sep; 12(1):15619. PubMed ID: 36114412
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Uchida M; Nakano K; Fujiwara M; Uesawa Y; Shimizu T
J Clin Pharm Ther; 2022 Aug; 47(8):1173-1180. PubMed ID: 35316861
[TBL] [Abstract][Full Text] [Related]
14. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
[TBL] [Abstract][Full Text] [Related]
15. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
Hosohata K; Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K
Clin Drug Investig; 2019 Apr; 39(4):363-368. PubMed ID: 30689189
[TBL] [Abstract][Full Text] [Related]
16. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
17. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Moreau P; Dimopoulos MA; Richardson PG; Siegel DS; Cavo M; Corradini P; Weisel K; Delforge M; O'Gorman P; Song K; Chen C; Bahlis N; Oriol A; Hansson M; Kaiser M; Anttila P; Raymakers R; Joao C; Cook G; Sternas L; Biyukov T; Slaughter A; Hong K; Herring J; Yu X; Zaki M; San-Miguel J
Eur J Haematol; 2017 Sep; 99(3):199-206. PubMed ID: 28504846
[TBL] [Abstract][Full Text] [Related]
18. Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Sato K; Mano T; Iwata A; Toda T
J Alzheimers Dis; 2021; 82(3):1333-1344. PubMed ID: 34151816
[TBL] [Abstract][Full Text] [Related]
19. Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Tanaka J; Koseki T; Kondo M; Ito Y; Yamada S
Anticancer Res; 2022 Sep; 42(9):4439-4451. PubMed ID: 36039456
[TBL] [Abstract][Full Text] [Related]
20. Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database.
Niinomi I; Oyama S; Inada A; Wakabayashi T; Hirai T; Kambara H; Iida T; Uchida M; Sano Y; Hosohata K
Int J Clin Pharmacol Ther; 2022 Sep; 60(9):402-407. PubMed ID: 35924642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
